IXHL News and Press, Incannex Healthcare Limited From 08/22/23

2023-08-22 10:22:39 ET More on Incannex Incannex Healthcare to redomicile from Australia to US, list on Nasdaq Incannex rises 9% after Australia approval to begin phase 1 trial of anti-inflammatory drug Incannex adds over 19% with positive data for sleep apnea candid...

MELBOURNE, Australia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychothe...

Highlights: Incannex subsidiary, Clarion Clinics Group Pty Ltd (Clarion) begins accepting registrations of interest in its psychedelic-assisted therapy (PAT) treatments ahead of planned Q3 opening. First clinic in Abbotsford, Melbourne, nearing fit-out completion. Clarion’...

MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide its quarterly activities report and appendix 4C for th...

MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine...

2023-07-21 10:34:46 ET Australian biotech Incannex ( NASDAQ: IXHL ) has submitted an investigational new drug application to the US Food and Drug Administration to begin clinical testing of its cannabinoid-based drug candidate IHL-42X for the treatment of obstructive sleep apnea. ...

MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine...

Highlights: Incannex has engaged Fortrea as the contract research organisation (‘CRO’) to manage the IND opening Phase 2/3 clinical trial investigating IHL-42X for treatment of OSA. The Phase 2/3 clinical trial will assess the safety and efficacy of IHL-42X in people w...

Highlights: Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain and Function of IHL-675A in Patients with Rheumatoid Arthritis. The Phase 2 tria...

2023-07-10 08:12:11 ET Pharmaceutical development company Incannex Healthcare ( NASDAQ: IXHL ) said on Monday that it intends to redomicile from Australia to the U.S., and is expected to list on Nasdaq. The process will take place through proposed schemes of arr...